The Omega-3 Index: The Rare Supplement Test With a Target Range

The full story

Order almost any supplement blood test and you get a number with no map. The result arrives flagged "in range", which mostly means it is in the range of the people who happened to walk through that lab. The omega-3 index is the unusual exception: a supplement biomarker whose cut-points were derived from mortality data rather than from the fat middle of a bell curve.

That is genuinely worth something. It is also where the story gets awkward, because the same two decades that pinned down the target range also produced the largest randomised trials of omega-3 supplementation ever run, and those trials mostly did not work. Holding both facts at once is the entire skill of reading this literature.

What the number actually is

The omega-3 index is EPA plus DHA expressed as a percentage of the total fatty acids in your red blood cell membranes. Because red cells turn over slowly, the NIH Office of Dietary Supplements describes the index as reflecting intake over roughly the previous 120 days. A season, not a breakfast. That slow averaging is its real advantage over a plasma fatty acid measurement, which drifts with your last few meals.

The same NIH page is blunt about the limits: experts have not established normal ranges for omega-3 status, and the Institute of Medicine never set specific intake recommendations for EPA, DHA or the other long-chain omega-3s. So the target is not a regulatory number handed down by a committee. It comes from one specific line of research, and it helps to know which.

Where 8 percent came from

The index was proposed in a 2004 paper in Preventive Medicine, which reported that an index at or above 8 percent was associated with the greatest cardioprotection and one at or below 4 percent with the least. Those are still the two numbers you see quoted, and it is worth saying plainly where they came from: observational and secondary-prevention data, not a trial that randomised anyone to an index.

A 2017 meta-analysis in Atherosclerosis did the arithmetic more carefully across 10 cohorts. The mean index was 6.1 percent, with a standard deviation of 2.1. Each standard deviation higher carried a hazard ratio of 0.85 for fatal coronary heart disease. Median values in the bottom and top fifths were 4.2 and 8.3 percent, and the authors estimated that moving from an index of 4 to an index of 8 corresponds to roughly 30 percent lower fatal coronary risk. Note the verb: corresponds. What this literature pins down is a floor and a target, not a ceiling.

The cohort evidence is strong, and it is specific

The best version of the observational argument is a 2021 pooled analysis in Nature Communications: 17 prospective cohorts, 42,466 people, 15,720 deaths, a median 16 years of follow-up. Death from all causes was 15 to 18 percent lower in the highest versus the lowest fifth of circulating long-chain omega-3s, with similar relationships for cardiovascular, cancer and other-cause death. Crucially, alpha-linolenic acid, the 18-carbon plant omega-3, showed no association at all.

A 2017 analysis in the Journal of Clinical Lipidology found the same shape in 6,501 women aged 65 to 80 followed a median 14.9 years, during which 1,851 died. Each standard deviation higher index carried a hazard ratio of 0.92 for total mortality, and EPA alone 0.89. Again, alpha-linolenic, arachidonic and linoleic acid showed nothing significant. The signal is marine, and it is consistent across very different populations.

What the evidence does not show

It does not show that raising your index changes your odds. This is the part the test kits leave out of the results email.

A 2019 randomised trial in the New England Journal of Medicine gave 1 gram a day of marine omega-3 to 25,871 US adults for a median 5.3 years: no reduction in major cardiovascular events, no reduction in invasive cancer, all-cause mortality unchanged. Total myocardial infarction, a secondary endpoint, was lower. A 2018 randomised trial in the same journal gave 1 gram a day against an olive-oil placebo to 15,480 people with diabetes for a mean 7.4 years and found no reduction in first serious vascular events and no reduction in death from any cause. A 2020 randomised trial in JAMA went to 4 grams a day in 13,078 statin-treated patients with high triglycerides and was stopped early for low probability of benefit; the primary composite landed at 12.0 versus 12.2 percent, and gastrointestinal adverse events were far more common on omega-3, 24.7 against 14.7 percent.

The 2020 Cochrane review is the summary judgement: 86 randomised trials, 162,796 participants, and little or no difference in all-cause mortality or in cardiovascular events, both graded high-certainty evidence. Coronary heart disease mortality and coronary events showed at most slight reductions on low-certainty evidence, with numbers needed to benefit in the hundreds. Effects did not differ by dose or by trial duration. One thing did move reliably: triglycerides fell about 15 percent, dose-dependently, on high-certainty evidence.

The exception is instructive rather than reassuring. The one large outcome trial with a clearly positive primary result used a purified EPA drug at 4 grams a day, not a fish oil capsule, in 8,179 statin-treated patients with triglycerides between 135 and 499 mg/dL. Over a median 4.9 years it cut the primary composite from 22.0 to 17.2 percent and cardiovascular death from 5.2 to 4.3 percent. It also raised hospitalisation for atrial fibrillation or flutter from 2.1 to 3.1 percent. A specific molecule, a specific dose, a specific population, and a real adverse signal. That is a different claim from "fish oil is good for you".

If you are going to test, know what moves the number

Here the data are unusually practical. A 2019 analysis in the American Journal of Clinical Nutrition pooled 1,422 people from 14 supplementation trials, averaging 1,983 mg a day of EPA plus DHA for a mean 13.6 weeks, and watched the index climb from 4.9 to 8.1 percent on average. Only three variables predicted an individual's response, and together they accounted for 62 percent of the variance:

• Baseline index. Where you start shapes how far you move.
• Dose.
• Chemical form. Triglyceride-form supplements raised the index about a full percentage point more than ethyl-ester forms, gram for gram.

That last one is the buried lede, and it has a concrete consequence. A population starting at 4.9 percent given 850 mg a day as an ethyl ester was predicted to reach only about 6.5 percent, short of the target, on a dose most people would consider respectable. These are the doses that were studied, not a recommendation for you; the point is that form and dose interact strongly enough that guessing is a waste of a blood draw.

The other practical consequence of that 120-day membrane turnover: retesting a month after changing something tells you very little. Wait a season, then measure.

So what is the test for

It tells you where you sit in a distribution that predicts mortality with unusual consistency across 17 cohorts and tens of thousands of deaths. That is real information, and if you are sitting near 4 percent it is information you almost certainly did not have. What it cannot do is promise that closing the gap buys you the outcome, because the trials that closed the gap pharmacologically did not deliver it, and the one that did used a drug, at a dose, with a side effect worth discussing with someone who knows your history. A number worth knowing and a number worth chasing are not the same thing, and most supplement marketing lives in the distance between them.